September 7 (SeeNews) - Bulgarian pharmaceutical company Sopharma [BUL:SFA] booked a 12% annual drop in sales in August as a result of weaker exports, it said on Wednesday.
The company registered 6% year-on-year growth in domestic sales in the month under review. Exports, however, dropped by an annual 21%, it said in a bourse filing.
Sopharma's sales in the first eight months of 2022 rose by 35%, driven by 37% growth in domestic sales and a 35% rise in exports, the company also said.
The drug producer reported last week a consolidated net profit of 43.4 million levs ($21.95 million/22.19 million euro) in the first half of 2022, up from 32.2 million levs a year earlier. Revenue in the six-month period climbed to 810.5 million levs from 771.2 million levs a year earlier.
By 1431 CEST on Wednesday, shares in Sopharma traded by 0.88% lower at 4.48 levs on the Bulgarian Stock Exchange.
(1 euro = 1.95583 levs)